| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H9N3O2 |
| Molecular Weight | 215.2081 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC1=NN2C(=C1)C3=CC=CC=C3NC2=O
InChI
InChIKey=XLUKOGNIEDDIMV-UHFFFAOYSA-N
InChI=1S/C11H9N3O2/c15-6-7-5-10-8-3-1-2-4-9(8)12-11(16)14(10)13-7/h1-5,15H,6H2,(H,12,16)
| Molecular Formula | C11H9N3O2 |
| Molecular Weight | 215.2081 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pirquinozol, a pyrazolo[1,5-c]quinazoline, is an orally effective anti-allergic agent as demonstrated in animal model systems. Pirquinozol is prodrug, requiring oxidation to SQ 12,903 for expression of maximum antiallergic activity. In-vitro, pirquinozol inhibits histamine release from rat mast cells in a manner similar to that observed for disodium cromoglycate (DSCG) and doxantrazole. In the rat, pirquinozol is not an antagonist of histamine in serotonin, in beta adrenergic agonist or a bronchodilator. Prophylactically administered pirquinozol inhibits immunologically-induced bronchospasm in rats passively sensitized with whole rat serum containing IgE anti-egg albumin, as measured by changes in both airway conductance and dynamic compliance.
